Literature DB >> 20608823

Translating genomic analyses into improved management of coronary artery disease.

Christopher T Johansen1, Matthew B Lanktree, Robert A Hegele.   

Abstract

Human genetic variation can modulate pathophysiologic processes that alter susceptibility to complex disease. Recent genomic analyses have sought to identify how common genetic variation alters susceptibility to coronary artery disease (CAD). From genome-wide association studies (GWAS), common genetic variants in several novel chromosomal loci have been associated with CAD. GWAS identified the 9p21 locus as the strongest independent genetic CAD risk factor, along with 11 additional loci that harbor common genetic variants associated with increased CAD risk. A thorough understanding of human genetic variation and genomic analyses will be crucial to understand how GWAS-identified loci increase susceptibility to CAD. This article outlines the relevance of genetic variation in the elucidation of novel CAD risk factors and the clinical utility of genetic variants in the management and treatment of CAD.

Entities:  

Mesh:

Year:  2010        PMID: 20608823     DOI: 10.2217/fca.10.28

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  3 in total

1.  The association between variants on chromosome 9p21 and inflammatory biomarkers in ethnically diverse women with coronary heart disease: a pilot study.

Authors:  Theresa M Beckie; Jason W Beckstead; Maureen W Groer
Journal:  Biol Res Nurs       Date:  2011-07       Impact factor: 2.522

2.  Introducing genetic testing for cardiovascular disease in primary care: a qualitative study.

Authors:  Jo B Middlemass; Momina F Yazdani; Joe Kai; Penelope J Standen; Nadeem Qureshi
Journal:  Br J Gen Pract       Date:  2014-05       Impact factor: 5.386

3.  The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease.

Authors:  A C J W Janssens; A A M Wilde; I M van Langen
Journal:  Neth Heart J       Date:  2011-01-15       Impact factor: 2.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.